Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.
Becker’s is proud to announce its 2024 list of hospitals and health systems recognized for excellence in oncology.
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue…
Big hospital systems are exploiting a Medicare loophole to charge older cancer patients thousands of dollars more per year for cancer treatment. Tell your members…
Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’ re speaking with…
Postintervention and 3-month follow-up assessments were evaluated to determine the feasibility and effectiveness of GET in managing distress in young Latino men with testicular cancer.
PHILADELPHIA (November 12, 2024) — For patients with cancer in the lower part of the rectum that has not spread to the lymph nodes, chemotherapy…
Sutter Medical Group (SMG) seeks to hire a BE/BC Bone Marrow Transplant Oncologist to join their dynamic team in Sacramento, CA. High income potential, (salary…
